Development of lysosomal storage in mice with targeted disruption of the beta-galactosidase gene: a model of human G(M1)-gangliosidosis.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Brain & development (Tokyo. 1979)

• Publication date

  2001-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0387-7604(01)00244-3PMID 11578847
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease

  2004cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• Prenatal Diagnosis of Lysosomal Storage Diseases

  1998cited by this paper
• Mouse Models of Human Lysosomal Diseases

  1998cited by this paper
• [beta-Galactosidosis (acid beta-galactosidase deficiency: GM1 gangliosidosis, Morquio B disease)].

  1998cited by this paper
• Neurological manifestations of knockout mice with β-galactosidase deficiency

  1997cited by this paper
• β-Galactosidase-deficient mouse as an animal model for GM1-gangliosidosis

  1997cited by this paper
• Neurological manifestations of knockout mice with beta-galactosidase deficiency.

  1997cited by this paper
• Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase.

  1997cited by this paper
• Mouse models of Tay–Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism

  1995cited by this paper
• Developmental changes of ganglioside expressions in postnatal rat cerebellar cortex.

  1995cited by this paper
• The Degradative Pathway of Gangliosides GM1 and GM2 in Neuro2a Cells by Sialidase

  1995cited by this paper
• Pathologic findings in fetal GM1 gangliosidosis.

  1986cited by this paper
• GM1-gangliosidosis: Chromosome 3 assignment of theβ-galactosidase-A gene (βGALA)

  1979cited by this paper
• GM1-gangliosidosis: chromosome 3 assignment of the beta-galactosidase-A gene (beta GALA).

  1979cited by this paper

• Base editing of the GLB1 gene is therapeutic in GM1 gangliosidosis patient-derived cells.

  2024cites this paper
• Hematopoietic stem cell gene therapy ameliorates CNS involvement in murine model of GM1-gangliosidosis

  2022influential citation
• TACG_A_206076 209..233

  2021cites this paper
• GM1 Gangliosidosis: Mechanisms and Management

  2021cites this paper
• Axonopathy and Reduction of Membrane Resistance: Key Features in a New Murine Model of Human GM1-Gangliosidosis

  2020cites this paper
• Mitochondria-associated ER membranes (MAMs) and lysosomal storage diseases

  2018cites this paper
• N -Octyl-β-Valienamine and N -Octyl-4- epi -β-Valienamine: Two Highly Potent Drug Candidates for Chemical Chaperone Therapy

  2017cites this paper
• Sucrose Induces Vesicle Accumulation and Autophagy

  2015cites this paper
• Approaches and Considerations Towards a Safe and EffectiveAdeno-Associated Virus Mediated Therapeutic Intervention for GM1-Gangliosidosis: A Dissertation

  2014cites this paper
• The genetics of sphingolipid hydrolases and sphingolipid storage diseases.

  2013cites this paper
• Sphingolipids: Basic Science and Drug Development

  2013cites this paper
• Elastin fragmentation and atherosclerosis progression: the elastokine concept.

  2013cites this paper
• Monitoring autophagy in lysosomal storage disorders.

  2009cites this paper
• 28 Mouse Models with Gene Deletions of Enzymes and Cofactors Involved in Sphingolipid Synthesis and Degradation

  2009cites this paper
• Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease

  2008influential citation
• Chemical chaperone therapy: clinical effect in murine GM1‐gangliosidosis

  2007cites this paper
• Neurologic, gastric, and opthalmologic pathologies in a murine model of mucolipidosis type IV.

  2007cites this paper
• The GM1 Gangliosidoses

  2007cites this paper
• Development and medical application of unsaturated carbaglycosylamine glycosidase inhibitors.

  2007cites this paper
• Beta-galactosidase deficiency: an approach to chaperone therapy.

  2006cites this paper
• Gangliosides as apoptotic signals in ER stress response

  2006cites this paper
• β-Galactosidase deficiency: An approach to chaperone therapy

  2006cites this paper
• Extracellular matrix and (re)myelination

  2006cites this paper
• Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice Published, JLR Papers in Press, February 1, 2005. DOI 10.1194/jlr.M400411-JLR200

  2005cites this paper
• Animal Models of Neurological Disorders

  2005cites this paper
• Lipid phase perturbations and the unfolded protein response.

  2004cites this paper
• GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis.

  2004cites this paper
• N‐butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis

  2004cites this paper
• Chemical chaperone therapy for brain pathology in GM1-gangliosidosis

  2003cites this paper
• New insights into elastin and vascular disease.

  2003cites this paper
• Lysosomes

  1966cites this paper
• Substrate Reduction Therapy Reduces Ganglioside Content in Postnatal Cerebrum- Brainstem and Cerebellum in a Mouse Model of Gm1 Gangliosidosis

  year unknowncites this paper